Hematology (all articles)
Case-control study | Association of anthracycline with heart failure in patients treated for breast cancer or lymphoma, 1985-2010
6 Feb, 2023 | 13:20h | UTCInvited Commentary: Heart Failure in Patients With Cancer Treated With Anthracyclines—Revisiting the Foundation of Cardio-Oncology- JAMA Network Open
Commentary on Twitter
Anthracycline is linked to double the rate of heart failure in patients with cancer vs matched controls, 7.4% at 15 years. https://t.co/SxlJkJ7oLR
— JAMA Network Open (@JAMANetworkOpen) February 3, 2023
SR | Efficacy of CAR-T cell therapy vs. auto-HSCT in relapsed or refractory diffuse large B-cell lymphoma
6 Feb, 2023 | 13:06h | UTC
Epidemiology, clinical presentation, and outcomes of 620 patients with eosinophilia in the intensive care unit
3 Feb, 2023 | 14:15h | UTC
Commentary on Twitter
🩸 Eosinophilia? Not uncommon in #ICU! Depending on timing, 2 subsets of pts, corresponding to different underlying diseases/different patterns of eosinophil-induced organ damage & requiring different etiological workups/management can be distinguished.
🗞️ https://t.co/nr1EHHnYGa pic.twitter.com/VBWpJKUGrv— Intensive Care Medicine (@yourICM) February 2, 2023
Transfusion thresholds for acute coronary syndromes — insights from the TRICS‐III trial and meta‐analysis
3 Feb, 2023 | 13:58h | UTC
Preliminary study suggests chemotherapy delivery in the afternoon may improve outcomes in patients with DLBC lymphoma
1 Feb, 2023 | 13:27h | UTCCommentaries:
Chemotherapy schedule affects treatment outcomes in female DLBCL patients – News Medical
RCT | Effects of once-weekly prophylaxis with Efanesoctocog Alfa in patients with severe Hemophilia A
30 Jan, 2023 | 01:14h | UTCEfanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Once-Weekly Efanesoctocog Alfa Beneficial in Severe Hemophilia A – HealthDay
Commentary on Twitter with a video summary
Efanesoctocog alfa is a new class of factor VIII replacement for hemophilia A that has a longer half-life than other factor VIII products, thus allowing once-weekly dosing. New research findings are summarized in a short video. https://t.co/YuXzifUh8m pic.twitter.com/POCAAfeEni
— NEJM (@NEJM) January 27, 2023
Practice Guidance | Anticoagulation in adult patients supported with extracorporeal membrane oxygenation
30 Jan, 2023 | 00:56h | UTC
RCT | IV ferric carboxymaltose vs. oral ferrous fumarate in anemic children with inflammatory bowel disease
30 Jan, 2023 | 00:18h | UTC
Cohort Study | Risk of malignant neoplasms of the gastrointestinal tract after blood or marrow transplant
30 Jan, 2023 | 00:23h | UTCMalignant Neoplasms of the Gastrointestinal Tract After Blood or Marrow Transplant – JAMA Oncology (link to abstract – $ for full-text)
Commentary: Risk of Subsequent Gastrointestinal Tract Malignancies After Blood or Marrow Transplantation – The ASCO Post
Commentary on Twitter
Exposure to cytarabine, etoposide and anthracyclines & chronic graft vs. host disease increase risk of colorectal, liver & esophageal cancer after BMT, providing evidence for appropriate evaluation & management in high-risk populations. https://t.co/UENFM1UWRw
— JAMA Oncology (@JAMAOnc) January 23, 2023
Cohort Study | Incidence and impact of anticoagulation-associated abnormal menstrual bleeding after VTE
27 Jan, 2023 | 12:04h | UTCInvited Commentary: The burden of heavy menstrual bleeding – Blood
Commentary on Twitter
Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism https://t.co/IEftFzyvRl pic.twitter.com/m09sP14inN
— Blood Journal (@BloodJournal) October 26, 2022
Post-trial follow-up | Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in early-stage unfavorable Hodgkin Lymphoma
27 Jan, 2023 | 11:58h | UTCCommentaries:
Review | Spotlight on vaccine-induced thrombosis and thrombocytopenia (VITT)
26 Jan, 2023 | 12:46h | UTCSpotlight on vaccine-induced thrombosis and thrombocytopenia (VITT) – Blood
2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis
24 Jan, 2023 | 14:29h | UTCKey Points: 2023 ACC Expert Consensus on Cardiac Amyloidosis – American College of Cardiology
Commentary on Twitter
.@ACCinTouch's 🆕 Expert Consensus Decision Pathway provides practical and timely guidance on the diagnosis and management of cardiac #amyloidosis, with an emphasis on comprehensive multidisciplinary care.
Learn more: https://t.co/1SunbtuQpO#JACC #CardioOnc #CardioTwitter pic.twitter.com/DLvFUpajHC
— JACC Journals (@JACCJournals) January 23, 2023
ASCO Guideline | Management of fever and neutropenia in pediatric patients with cancer and hematopoietic cell transplantation recipients
24 Jan, 2023 | 14:28h | UTC
RCT | Aspirin noninferior to low-molecular-weight heparin for thromboprophylaxis after a fracture
19 Jan, 2023 | 14:30h | UTCAspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: PREVENT CLOT Supports Aspirin for VTE Prevention in Trauma Fractures – TCTMD
M-A | Optimal timing of perioperative chemical thromboprophylaxis in elective major abdominal surgery
19 Jan, 2023 | 13:52h | UTCOptimal Timing of Perioperative Chemical Thromboprophylaxis in Elective Major Abdominal Surgery: A Systematic Review and Meta-analysis – Annals of Surgery (link to abstract – $ for full-text)
Review | Management of patients with lower-risk myelodysplastic syndromes
19 Jan, 2023 | 13:47h | UTCManagement of patients with lower-risk myelodysplastic syndromes – Blood Cancer Journal
Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score
18 Jan, 2023 | 14:37h | UTCSee calculator: https://vtepredict.com/
Commentary on Twitter
The effect of extended anticoagulant treatment for individual patients with venous thromboembolism: the results from the VTE-PREDICT risk score! #venous #thromboembolism #anticoagulant #bleeding #score#EHJ #cardiotwitter @ESC_Journals @escardio
https://t.co/u3NHWyB9rv pic.twitter.com/ifOFxaXV1I— EHJ Editor-in-Chief (@ehj_ed) January 17, 2023
Retrospective study | Supernumerary sex chromosome aneuploidies are associated with increased risk of VTE
18 Jan, 2023 | 14:22h | UTCAssociation of Supernumerary Sex Chromosome Aneuploidies With Venous Thromboembolism – JAMA (free for a limited period)
ESMO Guideline | Venous thromboembolism in cancer patients
15 Jan, 2023 | 20:21h | UTCVenous thromboembolism in cancer patients: ESMO Clinical Practice Guideline – Annals of Oncology
Related:
Cancer-associated venous thromboembolism – Nature Reviews Disease Primers
Infographic: Cancer-associated venous thromboembolism – Nature Reviews Disease Primers
NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
Review: venous and arterial thromboembolism in patients with cancer.
An investigational T-cell therapy shows promise against six viral infections common after stem cell transplants
13 Jan, 2023 | 13:10h | UTC
Development and validation of a clinical prediction model for the prediction of 5-year survival in Hodgkin Lymphoma
13 Jan, 2023 | 13:12h | UTCCommentaries:
Commentary from the author on Twitter (thread – click for more)
👉With the dust from #ASH22 settled, we are happy to highlight the inaugural output from the #HoLISTIC consortium: The Advanced-stage cHL International Prognostication Index (A-HIPI) presented at @ASH_hematology w/ simult pub in @ASCO @JCO (https://t.co/em6HENzngk). A thread 1/16 pic.twitter.com/2kicNMBEIj
— Andrew M. Evens, DO, MBA, MSc (@DrAEvens) December 31, 2022
SR | Laser therapy for retinopathy in sickle cell disease
12 Jan, 2023 | 13:02h | UTCLaser therapy for retinopathy in sickle cell disease – Cochrane Library
Summary: Laser therapy for retinopathy in sickle cell disease – Cochrane Library
Phase 2 RCT | Upfront autologous HSCT vs. carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in multiple myeloma
12 Jan, 2023 | 12:56h | UTCInvited Commentary: Upfront autologous transplantation still improving outcomes in patients with multiple myeloma – The Lancet Haematology
Review | Antithrombotic therapy after bioprosthetic aortic valve replacement
12 Jan, 2023 | 12:51h | UTC